Both Midatech Pharma plc (NASDAQ:MTP) and CRISPR Therapeutics AG (NASDAQ:CRSP) are each other’s competitor in the Biotechnology industry. Thus the contrast of their risk, analyst recommendations, institutional ownership, profitability, dividends, earnings and valuation.
Earnings and Valuation
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Midatech Pharma plc||1||0.00||10.72M||-0.85||0.00|
|CRISPR Therapeutics AG||56||0.00||34.37M||-0.46||0.00|
We can see in table 1 the earnings per share, gross revenue and valuation of Midatech Pharma plc and CRISPR Therapeutics AG.
Table 2 provides us Midatech Pharma plc and CRISPR Therapeutics AG’s return on assets, return on equity and net margins.
|Net Margins||Return on Equity||Return on Assets|
|Midatech Pharma plc||1,281,530,185.30%||0%||0%|
|CRISPR Therapeutics AG||60,907,318.80%||-2.6%||-2%|
Midatech Pharma plc and CRISPR Therapeutics AG Ratings and Recommendations are available on the next table.
|Sell Ratings||Hold Ratings||Buy Ratings||Rating Score|
|Midatech Pharma plc||0||0||0||0.00|
|CRISPR Therapeutics AG||0||0||3||3.00|
On the other hand, CRISPR Therapeutics AG’s potential upside is 5.39% and its consensus price target is $72.
Insider & Institutional Ownership
Roughly 0% of Midatech Pharma plc shares are held by institutional investors while 46.8% of CRISPR Therapeutics AG are owned by institutional investors. Midatech Pharma plc’s share held by insiders are 32.1%. Insiders Comparatively, held 0.4% of CRISPR Therapeutics AG shares.
Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.
|Performance (W)||Performance (M)||Performance (Q)||Performance (HY)||Performance (Y)||Performance (YTD)|
|Midatech Pharma plc||-13.16%||-33.52%||-55.67%||-58.21%||-75.69%||-62.25%|
|CRISPR Therapeutics AG||1%||49.37%||59.3%||63.07%||101.48%||153.31%|
For the past year Midatech Pharma plc had bearish trend while CRISPR Therapeutics AG had bullish trend.
CRISPR Therapeutics AG beats on 6 of the 10 factors Midatech Pharma plc.
Midatech Pharma PLC, a specialty pharmaceutical company, focuses on the development and commercialization of oncology and other therapeutic products in the United Kingdom, Turkey, other European countries, and the United States. It offers Oravig, an orally dissolving buccal tablet for oral thrush and oropharyngeal candidiasis in adults; Gelclair, an oral rinse gel for the management and relief of pain arising from oral lesions of various etiologies; Zuplenz, an oral soluble film for moderately emetogenic chemotherapy-induced nausea and vomiting, radiotherapy-induced nausea and vomiting, and post-operative nausea and vomiting; and Soltamox, an oral liquid solution of tamoxifen citrate for the prevention of breast cancer. The company also engages in the marketing of Ferralet 90, a prescription iron supplement for the treatment of anemias that are responsive to oral iron therapy; and Aquoral, an artificial saliva spray to provide relief from chemotherapy/radiation therapy. In addition, it is involved in the research and development of various product candidates in the areas of oncology and neuroscience, including ophthalmology; and immunotherapy. Midatech Pharma PLC was founded in 2000 and is headquartered in Abingdon, the United Kingdom.
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its proprietary clustered, regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9)gene-editing platform in Switzerland. The CRISPR/Cas9 technology allows for changes to genomic DNA. It has a collaboration agreement with Vertex Pharmaceuticals, Incorporated to develop, manufacture, commercialize, sell, and use therapeutics; a license agreement with Anagenesis Biotechnologies SAS; and a service agreement with MaSTherCell SA to develop and manufacture allogeneic CAR-T therapies. The company also has research collaboration agreements with Neon Therapeutics and Massachusetts General Hospital Cancer Center to develop novel T cell therapies for cancer. CRISPR Therapeutics AG is headquartered in Basel, Switzerland.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.